Australia’s illicit tobacco and nicotine markets are currently under significant pressure as regulatory bodies move to strengthen enforcement. Authorities have been granted expanded powers to manage non-compliant retailers, shifting the focus from traditional financial penalties to the comprehensive closure of illegal operations.
According to data from the Australian Bureau of Statistics, illicit supply has grown substantially, highlighting the necessity for regulated supply pathways. Total nicotine consumption is estimated to have increased by 40% between 2017 and 2025.
80% - Estimated share of tobacco and nicotine consumption from illicit sources in 2025.
12% - Estimated illicit share in 2017, illustrating the rapid expansion of the unregulated market.
Strategic Regulatory Importance
The current enforcement strategy aims to reduce access to non-compliant products that bypass health and safety controls. Regulated alternatives, such as registered therapeutic nicotine products, provide consistent standards and professional oversight in alignment with national requirements.
Utilising the suggested nicotine replacement therapy pathways ensures that individuals receive support through legitimate channels and adhere to the framework established by Australian regulators.
Enforcement Activity Indicators
Based on the ACOSH National Illicit Tobacco Ladder, state and territory responses are evaluated through supply-chain controls and enforcement activity levels.
- Queensland: 76%
- South Australia: 67%
- New South Wales: 48%
- Western Australia: 46%
- Victoria: 40%
- Tasmania: 36%
- ACT: 26%
- Northern Territory: 21%
While enforcement is critical for clearing the illicit market, equally important is ensuring those who are dependent on nicotine have access to reliable, evidence-based cessation pathways through a registered medical service.
The Clinical Perspective: Why Regulated Pathways Matter
The clinical validation of regulated nicotine delivery systems has been significantly bolstered by recent independent research. A landmark 2025 study conducted by researchers at the University of New South Wales (UNSW) provided compelling evidence that vaping is more effective than traditional nicotine replacement therapy (NRT)—such as nicotine gum or lozenges—specifically for helping socially disadvantaged smokers quit. This demographic often faces higher barriers to cessation, making the finding particularly significant for public health equity. The study underscores that when provided through structured, legitimate channels, these tools can offer a more viable path to cessation for those who have struggled with conventional methods. If you are ready to explore evidence-based support, you can start your clinical assessment here.
This research highlights the necessity of viewing regulated vaping not merely as an alternative product but as a critical clinical intervention. The efficacy noted in the UNSW trial was tied to the use of regulated products that provide a consistent and controlled nicotine delivery, mimicking the pharmacokinetic profile that many smokers require to manage withdrawal symptoms effectively. In an illicit market environment, this consistency is impossible to achieve, which can lead to treatment failure and a return to combustible tobacco. Regulated pathways ensure that clinical findings, such as those from UNSW, can be translated into safe practice under medical supervision.
Furthermore, integrating such evidence into the Australian clinical framework ensures that General Practitioners (GPs) can make informed recommendations based on the latest science. By aligning therapeutic availability with high-quality research, the Australian health system provides a model for harm minimisation that prioritises data over anecdote. The 2025 UNSW findings serve as a cornerstone for this approach, validating that for many, a transition through a regulated medical vape pathway is a superior strategy for achieving long-term freedom from tobacco. This clinical perspective is essential for moving beyond the confusion caused by unregulated supply and toward an evidence-based cessation landscape.
Evidence Base
Recent research underscores the critical need for this regulatory shift. A 2025 qualitative study identified significant gaps in parental knowledge and confusion surrounding vaping laws, highlighting the necessity for clear, consistent public communication about legitimate versus illicit supply channels. Furthermore, clinical guidelines from The Royal Australian College of General Practitioners (RACGP) emphasise that tobacco smoking remains the leading behavioural risk factor for preventable disease in Australia, validating the focus on regulated, professional cessation and nicotine dependency support over unregulated alternatives.
Why Regulated Pathways are Essential
The proliferation of illicit nicotine products nationally presents a multifaceted risk profile encompassing both acute health hazards and systemic supply chain vulnerabilities. Unregulated products often bypass the rigorous quality control standards mandated for therapeutic goods, leading to inconsistencies in nicotine concentration and the potential presence of prohibited additives or contaminants. Without the oversight of a regulatory body like the Therapeutic Goods Administration (TGA), consumers are exposed to devices that may lack basic electrical safety features or use carrier oils and flavourings that have not been evaluated for inhalation safety. These health risks are compounded by a lack of transparency in labelling, leaving users unaware of the actual chemical composition of the substances they inhale.
Beyond immediate health concerns, the illicit supply chain is frequently linked to broader organised crime networks, undermining public safety and siphoning revenue away from legitimate community services. These unregulated channels operate outside the legal framework, meaning there is no accountability for product defects or adverse reactions. In contrast, the regulated therapeutic pathway ensures that every product dispensed through a pharmacy has undergone a comprehensive assessment of its safety, quality, and efficacy. This oversight extends from the sourcing of raw materials to the final packaging, ensuring that patients receive a consistent and reliable product.
Therapeutic oversight also provides a clinical safety net. When nicotine products are accessed via a prescription, the process involves a consultation with a healthcare professional who can assess the patient's nicotine dependency and provide a structured treatment plan. This professional guidance is absent in the illicit market, where profit is prioritised over patient outcomes. By choosing regulated pathways, individuals are not only protecting their own health but also supporting a system that values transparency, clinical evidence, and long-term public health goals. The shift toward stronger enforcement in 2025 further distinguishes these safe, monitored channels from the dangerous volatility of the black market.
FAQs
What is the difference between illicit and therapeutic nicotine?
Therapeutic nicotine products are those registered with the TGA and intended for smoking cessation and nicotine dependency under medical supervision. They undergo strict quality control and safety testing. Illicit nicotine products are unregulated, often sold illegally by retailers without a prescription, and do not meet Australian health or safety standards. They may contain unknown chemicals, incorrect nicotine levels, and carry higher health risks.
Why have enforcement powers for tobacco retailers expanded in 2025?
In 2025, laws were strengthened to address the rapid rise of the illicit tobacco and nicotine market. Expanded powers allow authorities to not only issue fines but also to shut down non-compliant operations entirely. This shift aims to remove dangerous, unregulated products from the community and protect public health by ensuring that nicotine is only accessed through legitimate, regulated, and medically supervised pathways.
How can I verify if a product is compliant?
A compliant nicotine product in Australia (other than standard cigarettes) generally requires a prescription from a registered healthcare professional and must be dispensed by a pharmacy. You can verify a product's legitimacy by ensuring it is listed on the Australian Register of Therapeutic Goods (ARTG) or meets the TGA's specific standards for unapproved therapeutic goods. Products sold at convenience stores or online without a prescription are typically non-compliant.
Where can I find official support for quitting?
Official support is available on the Department of Health and Aged Care website, which provides comprehensive information on tobacco regulations. Quitline Australia (13 7848) offers professional counselling and resources. Additionally, consulting a General Practitioner (GP) is the recommended first step for accessing personalised clinical support and regulated nicotine replacement therapies or therapeutic vaping products.
Conclusion
Written by Dr.Craig Frawley BPharm Director Myduke Pty Ltd
As enforcement tightens, navigating the regulatory compliance framework is essential for accessing legitimate supply pathways. Avoiding unregulated retailers remains the safest and most effective approach for those seeking cessation and nicotine dependency support. If you're looking to quit or manage nicotine dependence, consult your healthcare provider and rely on official sources - such as the Department of Health and Aged Care and the RACGP - to ensure you're accessing safe, regulated care.
Regulatory Resources and Support
For official information on tobacco regulation and support services, please refer to the following resources:
References:
-
Australian Bureau of Statistics (ABS). (2025). Household consumption of illicit tobacco and nicotine products.
- University of New South Wales (UNSW). (2025). Research on the effectiveness of regulated vaping for cessation in socially disadvantaged smokers.
- Qualitative Study. (2025). Parental knowledge and awareness of vaping laws.
- The Royal Australian College of General Practitioners (RACGP). Clinical guidelines for supporting smoking cessation.
- Department of Health and Aged Care. Official resources on tobacco regulation and public health.
- Quitline Australia. Professional cessation counselling and resources.
- Australian Council on Smoking and Health (ACOSH). National Illicit Tobacco Ladder.
- Therapeutic Goods Administration (TGA). Notified vape list of goods for smoking cessation or nicotine dependence.
- Australian Register of Therapeutic Goods (ARTG).